Commercial Credit Report for Synthaverse SA

CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals. Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue. We also offer solutions that can help ease private company financial risk assessment. Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively.

A partial report preview for Synthaverse SA is shown below. Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database. To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

	Synthaverse SA
ul. Uniwersytecka 10
Phone: +48 815338221p:+48 815338221	LUBLIN, 20-029 Poland	Ticker: SVESVE

Business Summary

Synthaverse SA formerly known as Biomed Lublin Wytwornia Surowic i Szczepionek SA is a Poland-based company operating in the Life Science industry, dealing primarily with the production of medicines. The Company focuses on the production of drugs in the field of immunotherapy. Synthaverse SA offers its services in the field such as: oncological immunotherapy, Immunotherapy in Serological Conflict, Passive immunotherapy in hepatitis B, Active anti-tuberculosis immunotherapy, Gynecology and Proctology, Probiotics, Laboratory reagents. The Company offers injection drugs, lyophilisates of active substances in sterile sealed vials, active substances and drugs based on surface and submerged biological culture, suppository forms of drugs. The Company supplies its products to 50 countries around the world.

(Source: 10-K405)

Scores and Ratings

FRISK^® Score	Z'' Score	PAYCE^® Score	DBT Index	Moody's Rating	Fitch Rating	DBRS Rating
Yes	Yes	-	Yes	-	-	-

Financials, News and Filings

Latest Statement	Last Audit	News	SEC Filings	Bankruptcy Filings	Suit & Judgment Filings	Tax Lien Filings
12/31/2023	12/31/2023	Yes	-	-	-	-

Industries

SIC Code	Description
2836	Biological products, except diagnostic substances

Officers and Directors

Title	Name	Age	Title Date	Start Date
Chairman of the Supervisory Board	JaroslawBlaszczak		12/20/2016	6/30/2016
Chairman of the Management Board	PiotrFic	52	11/30/2020	2/1/2019
Vice Chairman of the Supervisory Board	WiktorNapiora	62	12/20/2016
6 additional Officers and Directors records available in full report.

Business Names

Business Name
BML
SVE

General Information

Number of Employees:	239	(As of 12/31/2023)
Outstanding Shares:	70,260,410	(As of 12/31/2023)
Stock Exchange:	WAR
Fax Number:	+48 815338060

SITE MAP | ABOUT US | DIRECTORY | STOCK QUOTE: CRMZ | SIGN IN